Breakdown | |||||
TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
884.21K | 1.14M | 1.35M | 1.30M | 180.00 | 51.19K | Gross Profit |
884.21K | 1.14M | 1.31M | 1.28M | 1.02M | 31.67K | EBIT |
-2.14M | -2.27M | -4.60M | -4.60M | -3.80M | -2.71M | EBITDA |
-2.14M | -2.27M | -3.19M | -3.28M | -3.71M | -2.64M | Net Income Common Stockholders |
-2.26M | -2.34M | -3.45M | -3.99M | -3.86M | -3.00M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
9.99K | 808.97K | 2.95M | 1.28M | 5.78M | 2.72M | Total Assets |
1.04M | 2.03M | 4.63M | 3.94M | 6.98M | 3.00M | Total Debt |
1.90M | 28.93K | 70.21K | 6.90M | 8.68M | 8.28M | Net Debt |
1.89M | -780.04K | -2.88M | 5.62M | 2.90M | 5.60M | Total Liabilities |
3.71M | 539.26K | 1.11M | 8.36M | 9.88M | 9.71M | Stockholders Equity |
-2.67M | 1.49M | 3.52M | -4.42M | -2.90M | -6.71M |
Cash Flow | Free Cash Flow | ||||
-1.41M | -2.10M | -2.37M | -4.46M | -3.26M | -3.00M | Operating Cash Flow |
-1.44M | -2.03M | -2.35M | -4.44M | -3.26M | -3.00M | Investing Cash Flow |
268.04K | -67.90K | -17.13K | -21.00K | 0.00 | 0.00 | Financing Cash Flow |
-41.28K | -41.28K | 4.04M | -34.55K | 6.35M | 5.64M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
56 Neutral | AU$40.27M | ― | -36.95% | ― | ― | 11.11% | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
44 Neutral | AU$69.85M | ― | -45.40% | ― | 13.61% | -55.12% | |
40 Underperform | $110.99M | ― | -46.65% | ― | 96.20% | 80.90% | |
38 Underperform | AU$2.56M | ― | -163.00% | ― | ― | 9.19% | |
36 Underperform | $3.32M | ― | -119.28% | ― | ― | 64.10% |
Vectus Biosystems Limited has been actively advancing its commercialization efforts for its lead compound, VB0004, and other drug candidates, with a focus on potential collaborations in China. The company has validated VB0004’s safety profile in recent clinical trials and is exploring faster approval paths in China. Financially, Vectus has reduced operating costs and is seeking licensing opportunities to support further clinical studies, with cash-on-hand reported at $370,000 as of March 2025.
Vectus Biosystems Limited announced the issuance of 25,000 new fully paid ordinary shares following the exercise of options by two contractors under the Employee Incentive Plan. This move reflects the company’s ongoing efforts to incentivize and retain talent, potentially strengthening its operational capabilities and market position.
Vectus Biosystems Limited announced the issuance of 25,000 ordinary fully paid securities to be quoted on the ASX, effective March 12, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing research and development efforts, potentially strengthening its market position and offering value to stakeholders.